[126] Serious harms with long-term PPI use in older adults
Proton pump inhibitors (PPIs) were introduced in 1988. Health Canada, professional, and academic groups all agree that they should be prescribed at the lowest dose and for the shortest duration appropriate to the condition treated. However, PPI use continues to expand. Between 2000 and 2018 BC’s population grew by 20%, but use of PPIs increased by 257%. In 2018, 442,559 British Columbians (9% of … [Read more...]
[125] Can prescribers avoid contributing to opioid use disorder?
Case vignette: A 21 y/o has surgery for a condition expected to improve. He fills a discharge prescription for 5 days of an opioid at a standard dose. At 1-week follow-up with his family doctor for suture removal, he describes ongoing pain. Is a renewal of opioid appropriate, potentially dangerous, or both? Aggressive promotion of opioids for chronic non-cancer pain (CNCP) began in the … [Read more...]
Hitting the target but missing the point: The case against LDL and A1C targets
Dr. Aaron Tejani, PharmD gave this presentation on October 5th, 2019 in Vancouver, BC at the "Bringing Best Evidence to Clinicians" medical education conference marking the 25th anniversary of the UBC Therapeutics Initiative. Dr. Tejani is a clinical assistant professor with the Faculty of Pharmaceutical Sciences (University of British Columbia), Medication use evaluation pharmacist with Lower … [Read more...]
[Special Edition: March 2020] Pill splitting: Making the most of meds in a time of need
Français | Español | Português | 繁體中文 | 简体中文| عربي Clinical vignette A 54 year-old mechanic with type 2 diabetes and hypertension had a myocardial infarction in 2015. He currently takes ASA 81mg/d (over the counter) plus 6 generic prescription drugs dispensed monthly: atorvastatin 40mg/d ramipril 5mg/d empagliflozin 25mg/d escitalopram 10mg/d sildenafil 50mg 4 … [Read more...]
Rapid monitoring of health services utilization following a shift in coverage from brand name to biosimilar drugs in British Columbia—An interim report
Pharmacoepidemiol Drug Saf. 2020;1–8. First published: 28 May 2020. Fisher A, Kim JD, Dormuth CR Purpose: We explored changes in health services utilization associated with the Biosimilars Initiative introduced in British Columbia on May 27, 2019. To maintain drug coverage, the policy requires users of originator infliximab or etanercept to transition to biosimilar versions. We present a … [Read more...]
[Jun 24] Methods Speaker Series: Visualizing public health data: strategies and tools
TI Methods Speaker Series The TI Methods Speaker Series are offered free of charge and everyone is welcome. The event is held at noon on the last Wednesday of each month and used to take place in Rudy North Lecture Theatre (CBH 101) in the Centre for Brain Health, UBC Point Grey Campus. During the COVID-19 pandemic, while physical distancing measures are in effect, the TI Methods Speaker Series … [Read more...]
Acetaminophen vs. NSAIDs during COVID-19 pandemic
TREATING FEVER AND PAIN in the time of COVID-19 Many people are asking doctors for information about whether it is safe to use NSAID drugs now. Examples of this drug class include ibuprofen (generic, Advil, Motrin), naproxen (generic, Aleve), diclofenac (generic, Voltaren, Arthrotec), celecoxib (Celebrex), meloxicam (Mobicox) and many others. Feeling an increase in your body temperature can … [Read more...]
[Jun 10] Shedding light on risks with anticholinergic drug use – Practical tips for patient care
TI Best Evidence Webinar Shedding light on risks with anticholinergic drug use – Practical tips for patient care This event has already taken place. Scroll down to view a video recording of the webinar. PRESENTER: Dr. Aaron M Tejani, PharmD. DATE: Wednesday, June 10, 2020 CME CREDITS: MainPro+/MOC Section 1 credits: 1.0. You must register, attend the webinar and complete the … [Read more...]
[VIDEO] Pill splitting: Making the most of meds in a time of need
Sodium‐glucose Cotransporter 2 Inhibitors and the Risk for Urosepsis – A Multi‐site Prevalent New‐user Cohort Study
First published: 08 May 2020 Abstract AIMS The United States Food and Drug Administration has warned of an increased risk of serious urinary tract infection (UTI) and Fournier’s gangrene in patients with diabetes mellitus type 2 treated with sodium–glucose cotransporter 2 inhibitors (SGLT2i). However, evidence on these risks is limited. We aimed to compare urosepsis rates in SGLT2i users with … [Read more...]
- 1
- 2
- 3
- …
- 28
- Next Page »
